Clinical Context
A typical patient is an adult or pediatric oncology patient with a suspected or confirmed mast cell tumor or gastrointestinal stromal tumor where targeted molecular information about the v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) gene will inform prognosis or eligibility for targeted therapy. A surgical or interventional oncology team or outpatient clinic identifies a tissue specimen (formalin-fixed paraffin-embedded tumor block or fresh/frozen tissue) or a peripheral blood sample requiring molecular testing. The specimen is accessioned into the molecular pathology laboratory where a pathology requisition documents clinical history, relevant diagnoses, specimen type, and physician ordering information. A molecular technologist performs DNA extraction and a targeted partial gene sequence analysis of KIT, typically covering hotspot exons such as exon 8, 11, 13, 17, and 18. Results are analyzed by a molecular pathologist, who issues a report interpreting detected pathogenic or likely pathogenic variants, variants of uncertain significance, or no actionable variants. The report is routed back to the ordering oncologist or surgeon to guide treatment decisions (for example, tyrosine kinase inhibitor selection), clinical trial eligibility, or prognostic counseling. Typical sites of service include hospital-based molecular pathology laboratories, reference diagnostic laboratories, and outpatient specialty clinics that collect and submit specimens.